Sanara MedTech Inc.
Qualité des données : 100%
SMTI
Nasdaq
Manufacturing
Measuring & Analyzing Instruments
16,53 €
▼
0,44 €
(-2,59%)
Cap. Boursière: 155,66 M
Prix
16,98 €
Cap. Boursière
155,66 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue grew 43,76% annually over 5 years — strong growth
Debt/Equity of 7,33 — high leverage
Generating 2,16 M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 24,79%
Capital efficient — spends only 4,49% of revenue on capex
Interest coverage of 1,08× — tight debt servicing
Croissance
Revenue Growth (5Y)
43,76%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)18,97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-180,81%
En dessous de la moyenne du secteur (-53,53%)
ROIC8,39%
Net Margin-36,43%
Op. Margin7,08%
Sécurité
Debt / Equity
7,33
Au-dessus de la moyenne du secteur (0,31)
Current Ratio1,80
Interest Coverage1,08
Valorisation
PE (TTM)
-4,14
En dessous de la moyenne du secteur (-1,48)
P/B Ratio25,31
EV/EBITDA16,52
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -4,1 | -1,5 |
| P/B | 25,3 | 1,6 |
| ROE % | -180,8 | -53,5 |
| Net Margin % | -36,4 | -41,5 |
| Rev Growth 5Y % | 43,8 | 1,8 |
| D/E | 7,3 | 0,3 |
Objectif de Cours des Analystes
1 analyste
Buy
Actuel
16,53 €
Objectif
36,00 €
36,00 €
36,00 €
36,00 €
Prévisions
BPA Prévisionnel
-1,17 €
CA Est.
0,0
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 | — | 0,0 | — |
| FY2026 |
0,16 €
0,16 € – 0,16 €
|
118,60 M | 1 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
0,02 €
0,02 € – 0,02 €
|
29,40 M | 1 |
| 2026 Q1 |
-0,04 €
-0,04 € – -0,04 €
|
26,90 M | 1 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | 0,11 € | -0,19 € | -272,7% |
| Q32025 | -0,22 € | -3,52 € | -1537,2% |
| Q22025 | -0,44 € | -0,23 € | +47,7% |
| Q12025 | -0,51 € | -0,41 € | +18,8% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 18,97% | Revenue Growth (3Y) | 25,96% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 43,76% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 103,12 M | Net Income (TTM) | -37,56 M |
| ROE | -180,81% | ROA | -44,23% |
| Gross Margin | 92,71% | Operating Margin | 7,08% |
| Net Margin | -36,43% | Free Cash Flow (TTM) | 2,16 M |
| ROIC | 8,39% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 7,33 | Current Ratio | 1,80 |
| Interest Coverage | 1,08 | Asset Turnover | 1,21 |
| Working Capital | 13,87 M | Tangible Book Value | -18,55 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4,14 | Forward P/E | N/A |
| P/B Ratio | 25,31 | P/S Ratio | 1,51 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 16,52 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 1,39% | ||
| Market Cap | 155,66 M | Enterprise Value | 185,81 M |
| Per Share | |||
| EPS (Diluted TTM) | -4,36 | Revenue / Share | 11,25 |
| FCF / Share | 0,24 | OCF / Share | 0,74 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 4,49% | FCF Conversion | -5,75% |
| SBC-Adj. FCF | -2,84 M | Growth Momentum | -24,79 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 103,12 M | 86,67 M | 64,99 M | 45,84 M | 24,14 M |
| Net Income | -37,56 M | -9,66 M | -4,30 M | -7,94 M | -7,99 M |
| EPS (Diluted) | -4,36 | -1,14 | -0,52 | — | — |
| Gross Profit | 95,60 M | 78,53 M | 57,14 M | 39,48 M | 21,83 M |
| Operating Income | 7,30 M | -6,72 M | -4,22 M | -12,23 M | -7,38 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 5,07 M | 5,70 M | 4,13 M | 3,37 M | 558 704,0 |
| SG&A Expenses | 78,72 M | 76,56 M | 56,99 M | 45,98 M | — |
| D&A | 3,95 M | 4,92 M | 3,68 M | 2,37 M | 596 975,0 |
| Interest Expense | 6,76 M | 3,13 M | 475 783,0 | 284 746,0 | 711,0 |
| Income Tax | 48 380,0 | -48 380,0 | -5,84 M | -5,84 M | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 72,94 M | 88,09 M | 73,87 M | 61,04 M | 36,40 M |
| Total Liabilities | 67,01 M | 49,18 M | 29,28 M | 19,32 M | 6,24 M |
| Shareholders' Equity | 5,94 M | 39,40 M | 44,83 M | 41,83 M | 30,64 M |
| Total Debt | 45,97 M | 30,69 M | 9,69 M | — | — |
| Cash & Equivalents | 16,58 M | 15,88 M | 5,15 M | 8,96 M | 18,65 M |
| Current Assets | 33,54 M | 33,31 M | 19,01 M | 20,62 M | 24,61 M |
| Current Liabilities | 18,63 M | 15,29 M | 13,77 M | 12,81 M | 6,02 M |
{"event":"ticker_viewed","properties":{"ticker":"SMTI","listing_kind":"stock","pathname":"/stocks/smti","exchange":"Nasdaq","country":"US"}}

